Leonteq Securities AG Purchases Shares of 56,790 Intellia Therapeutics, Inc. $NTLA

Leonteq Securities AG purchased a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 56,790 shares of the company’s stock, valued at approximately $511,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Farallon Capital Management LLC acquired a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at about $10,486,000. Vanguard Group Inc. raised its stake in shares of Intellia Therapeutics by 1.8% in the 3rd quarter. Vanguard Group Inc. now owns 11,044,820 shares of the company’s stock valued at $190,744,000 after purchasing an additional 192,651 shares during the period. Jupiter Asset Management Ltd. acquired a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at about $23,519,000. Contrarius Group Holdings Ltd raised its stake in shares of Intellia Therapeutics by 279.4% in the 3rd quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock valued at $101,719,000 after purchasing an additional 4,337,428 shares during the period. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd raised its stake in shares of Intellia Therapeutics by 68.0% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 494,468 shares of the company’s stock valued at $8,539,000 after purchasing an additional 200,081 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $12.60 on Friday. The stock’s 50-day simple moving average is $13.53 and its 200 day simple moving average is $11.96. The company has a market cap of $1.76 billion, a P/E ratio of -3.56 and a beta of 1.93. Intellia Therapeutics, Inc. has a 52-week low of $6.83 and a 52-week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.The business had revenue of $15.05 million during the quarter, compared to analysts’ expectations of $13.81 million. During the same quarter last year, the company posted ($1.10) earnings per share. As a group, equities analysts predict that Intellia Therapeutics, Inc. will post -3.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on NTLA shares. Morgan Stanley lifted their target price on Intellia Therapeutics from $11.00 to $15.00 and gave the company an “equal weight” rating in a research report on Monday, April 27th. Sanford C. Bernstein lifted their target price on Intellia Therapeutics from $13.00 to $17.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Wells Fargo & Company lifted their target price on Intellia Therapeutics from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Tuesday, March 3rd. Leerink Partners set a $35.00 target price on Intellia Therapeutics in a research report on Monday, April 27th. Finally, Robert W. Baird lifted their target price on Intellia Therapeutics from $7.00 to $13.00 and gave the company a “neutral” rating in a research report on Monday, April 27th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $20.25.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.